Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis

被引:5
|
作者
Erbe, Amanda W. [1 ,4 ]
Kendzia, Dana [2 ]
Busink, Ellen [2 ]
Carroll, Suzanne [3 ]
Aas, Eline [1 ]
机构
[1] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[2] Fresenius Med Care, Market Access & Hlth Econ, Bad Homburg, Germany
[3] Fresenius Med Care UK Ltd, Hlth Econ, Market Access & Prod Management, Huthwaite, England
[4] Univ Oslo, Dept Hlth Management & Hlth Econ, POB 1089 Blindern, Oslo 0317, Norway
关键词
economic evaluation; home hemodialysis; home -to -home transition; patient pathway management; peritoneal; dialysis; renal replacement therapy; QUALITY-OF-LIFE; PERITONEAL-DIALYSIS; HEMODIALYSIS; DISEASE; UTILITY; RISK;
D O I
10.1016/j.jval.2023.02.009
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: This study aimed to determine the lifetime cost-effectiveness of increasing home hemodialysis as a treatment option for patients experiencing peritoneal dialysis technique failure compared with the current standard of care.Methods: A Markov model was developed to assess the lifetime costs, quality-adjusted life-years, and cost-effectiveness of increasing the usage an integrated home dialysis model compared with the current patient pathways in the United Kingdom. A secondary analysis was conducted including only the cost difference in treatments, minimizing the impact of the high cost of dialysis during life-years gained. Sensitivity and scenario analyses were performed, including analyses from a societal rather than a National Health Service perspective.Results: The base-case probabilistic analysis was associated with incremental costs of & POUND;3413 and a quality-adjusted life-year of 0.09, resulting in an incremental cost-effectiveness ratio of & POUND;36341. The secondary analysis found the integrated home dialysis model to be dominant. Conclusions on cost-effectiveness did not change under the societal perspective in eitherConclusions: The base-case analysis found that an integrated home dialysis model compared with current patient pathways is likely not cost-effective. These results were primarily driven by the high baseline costs of dialysis during life-years gained by patients receiving home hemodialysis. When excluding baseline dialysis-related treatment costs, the integrated home dialysis model was dominant. New strategies in kidney care patient pathway management should be explored because, under the assumption that dialysis should be funded, the results provide cost-effectiveness evidence for an integrated home dialysis model.
引用
收藏
页码:984 / 994
页数:11
相关论文
共 50 条
  • [41] Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model
    Pritchard, Clive
    Kutikova, Lucie
    Pitman, Richard
    Lai, Kira Zhi Hua
    Beyhaghi, Hadi
    Gibbons, Iiana
    Erbe, Amanda
    Zivkovic-Gojovic, Marija
    Cosgrove, Catherine
    Sculpher, Mark
    Salisbury, David
    VACCINES, 2025, 13 (02)
  • [42] THE ROLE OF STRUCTURAL SENSITIVITY ANALYSIS IN THE MODELLING OF COST-EFFECTIVENESS (COST-UTILITY) IN PARKINSON'S DISEASE IN THE UNITED STATES AND UNITED KINGDOM
    Ratcliffe, A. E.
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [43] COST-EFFECTIVENESS OF INTRODUCING NUVAXOVID TO COVID-19 VACCINATION IN THE UNITED KINGDOM: A DYNAMIC TRANSMISSION MODEL
    Pritchard, C.
    Kutikova, L.
    Pitman, R.
    Lai, K.
    Beyhaghi, H.
    Gibbons, I
    Erbe, A.
    Cosgrove, C.
    Sculpher, M.
    Salisbury, D.
    VALUE IN HEALTH, 2024, 27 (12) : S74 - S74
  • [44] COST-EFFECTIVENESS OF BONT-A PRODUCTS FOR TREATMENT OF PEDIATRIC SPASTICITY IN THE UNITED KINGDOM
    Danchenko, Natalya
    Johnston, Karissa
    Bolatova, Talshyn
    Whalen, John
    TOXICON, 2021, 190 : S15 - S15
  • [45] LIFETIME COST-EFFECTIVENESS OF CONCOMITANT AORTIC VALVE REPLACEMENTS IN FRANCE AND THE UNITED KINGDOM
    Pradelli, L.
    Giardina, S.
    Ranucci, M.
    VALUE IN HEALTH, 2013, 16 (07) : A531 - A531
  • [46] Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
    Verhoef, T. I.
    Redekop, W. K.
    Langenskiold, S.
    Kamali, F.
    Wadelius, M.
    Burnside, G.
    Maitland-van der Zee, A-H
    Hughes, D. A.
    Pirmohamed, M.
    PHARMACOGENOMICS JOURNAL, 2016, 16 (05): : 478 - 484
  • [47] COST-EFFECTIVENESS OF COMPUTER SOLUTIONS IN DIALYSIS
    SARGENT, JA
    CLARK, RA
    PAGET, M
    KINGSTON, WW
    DIALYSIS & TRANSPLANTATION, 1991, 20 (04) : 179 - &
  • [48] COST-EFFECTIVENESS OF SCREENING AND TREATMENT OF ALZHEIMER'S DISEASE WITH DONEPEZIL IN THE UNITED KINGDOM
    Getsios, D.
    Blume, S.
    Ishak, K. J.
    MacLaine, G.
    VALUE IN HEALTH, 2009, 12 (03) : A191 - A191
  • [49] COST-EFFECTIVENESS ISSUES FOR HOME IV THERAPY IN THE UNITED-STATES
    ALLEN, R
    HOSPITAL FORMULARY, 1993, 28 : 37 - 40
  • [50] Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom
    McKenna, C.
    Palmer, S.
    Rodgers, M.
    Chambers, D.
    Hawkins, N.
    Golder, S.
    Van Hout, S.
    Pepper, C.
    Todd, D.
    Woolacott, N.
    HEART, 2009, 95 (07) : 542 - 549